Preimplantation genetic testing for aneuploidy (PGT-A) seeks to identify preimplantation embryos with a normal chromosome complement (Euploid) during in vitro fertilization (IVF). By sifting out embryos with abnormal chromosome numbers (Aneuploidy), PGT-A should theoretically improve pregnancy success. However, earlier versions of PGT-A were ineffective, and in some cases, detrimental, due to biopsy-induced trauma and because the technology at the time could analyze only a fraction of all chromosomes. More recently, the emergence of technologies enabling all chromosomes to be analyzed and a switch to less traumatic blastocyst-stage biopsy have seen widespread uptake of PGT-A. Assessing the full impact of blastocyst biopsy PGT-A requires consideration of multiple factors, including embryonic mosaicism, sensitivity of the technological platform used, embryo loss during long-term in vitro culture, embryo cryopreservation and inter-clinic variability in expertise. This study presents a review of the Preimplantation genetic testing for aneuploidy (PGT-A) versus morphology selection in clinical pregnancy outcome. And was conducted on 694 infertile women undergoing ICSI cycles with poor prognosis; poor responder women whose age is 38 or more, required 375 I.U. of gonadotropin or more per day to well stimulate their follicles and with history of previous failed ICSI. PGT-A was performed for 347 cases for 24 chromosomes by next generation sequencing. The other 347 were had unscreened embryo transfer. The result showing there are no statistically significant variations in a Chi-squared test with a p-value of more than 0.01 was conducted in the positive and negative results when comparing Frozen Unscreened ET samples to the Frozen screened ET samples. Still there are small differences between them as the screened samples had more positive results and less negative results.